Wells Fargo & Company MN boosted its holdings in Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) by 90.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 96,945 shares of the company’s stock after buying an additional 45,922 shares during the period. Wells Fargo & Company MN owned 0.09% of Eyepoint Pharmaceuticals worth $159,000 at the end of the most recent reporting period.
Separately, Strs Ohio acquired a new stake in Eyepoint Pharmaceuticals in the 2nd quarter worth about $27,000. 58.62% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:EYPT opened at $2.11 on Friday. The company has a current ratio of 5.46, a quick ratio of 5.31 and a debt-to-equity ratio of 1.75. Eyepoint Pharmaceuticals Inc has a one year low of $1.19 and a one year high of $3.78. The business’s 50-day simple moving average is $1.73 and its 200 day simple moving average is $1.64.
A number of analysts have issued reports on the company. B. Riley decreased their price target on Eyepoint Pharmaceuticals from $5.75 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, September 24th. ValuEngine upgraded Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Zacks Investment Research downgraded Eyepoint Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday. HC Wainwright restated a “buy” rating and issued a $4.50 price objective on shares of Eyepoint Pharmaceuticals in a report on Wednesday, September 25th. Finally, Guggenheim assumed coverage on Eyepoint Pharmaceuticals in a report on Thursday, September 12th. They issued a “buy” rating and a $4.00 price objective on the stock. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $3.69.
Eyepoint Pharmaceuticals Profile
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.
Read More: Market Timing
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.